Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus TRYMEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus TRYMEX.
CORTIFOAM vs TRYMEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
TRYMEX is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity by blocking the reuptake of serotonin at the presynaptic neuron, enhancing neurotransmission in the central nervous system.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
Adults: 500 mg orally twice daily or 1 g intravenously once daily.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; extends to 30-40 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Renal excretion of unchanged drug accounts for 60-70% of dose; biliary/fecal elimination contributes 20-30%, with <5% as metabolites.
Category C
Category C
Corticosteroid
Corticosteroid